Literature DB >> 1759831

Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding.

G Potel1, N P Chau, B Pangon, B Fantin, J M Vallois, F Faurisson, C Carbon.   

Abstract

The relative importance of pharmacokinetic and pharmacodynamic parameters for the feasibility of a single daily dose (SDD) of antibiotics remains to be established. Therefore, we studied the relationship between in vitro bacteriological parameters (MIC, MBC, and killing rate [KR], defined as the reduction in the inoculum within 3 h), pharmacokinetic parameters (t1/2 and protein binding [PB], and in vivo antibacterial effect of a single antibiotic dose in an experimental rabbit model of Escherichia coli endocarditis. Nine antibiotics were investigated: two aminoglycosides, two quinolones, and five beta-lactams. For each drug, the minimal effective dose (MED) (in milligrams per kilogram) was defined as the lowest dose able to achieve a significant difference (P less than 0.05) of CFU in the vegetations in comparison with controls 24 h after a single intravenous injection. Aminoglycosides and quinolones had the lowest MEDs, followed by beta-lactams. Univariate regression analysis showed that KR was the major determinant of MED. A stepwise regression analysis showed that t1/2 significantly improved the predictive value of KR, while PB, MIC, and MBC did not. The final equation was MED = 1,586-238 KR-297 t1/2 (r = 0.90, P = 0.01). We concluded that the pharmacodynamic parameters (especially the high KR) of aminoglycosides and quinolones explained their low MEDs and might allow SDD. In contrast, the low KR of beta-lactams emphasized the critical importance of a long t1/2, as for ceftriaxone, allowing the use of this beta-lactam alone in SDD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759831      PMCID: PMC245330          DOI: 10.1128/AAC.35.10.2085

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  A study of amikacin given once versus twice daily in serious infections.

Authors:  R Maller; B Isaksson; L Nilsson; L Sörén
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

2.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

3.  Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation.

Authors:  G Potel; J Caillon; B Fantin; J Raza; F Le Gallou; J Y Lepage; P Le Conte; D Bugnon; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis.

Authors:  B Fantin; B Pangon; G Potel; J M Vallois; F Caron; A Bure; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.

Authors:  B Pangon; V Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat.

Authors:  M J Ingerman; P G Pitsakis; A F Rosenberg; M E Levison
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

7.  Treatment failures of cefotaxime and latamoxef in meningitis caused by Enterobacter and Serratia spp.

Authors:  R H Eng; C E Cherubin; J C Pechere; T R Beam
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790

8.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Authors:  J E Leggett; B Fantin; S Ebert; K Totsuka; B Vogelman; W Calame; H Mattie; W A Craig
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

9.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

10.  Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Authors:  J E Kapusnik; C J Hackbarth; H F Chambers; T Carpenter; M A Sande
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

View more
  12 in total

1.  Pharmacodynamics, a tool for a better use of antibiotics?

Authors:  F Crokaert
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

Review 2.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

3.  A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.

Authors:  P H Berg; E O Voit; R L White
Journal:  Bull Math Biol       Date:  1996-09       Impact factor: 1.758

Review 4.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

5.  In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis.

Authors:  M E Juvin; G Potel; J Caillon; Y Q Xiong; D Bugnon; P Le Conte; D I Baron; H B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

7.  Temporal variation in nephrotoxicity of low doses of isepamicin in rats.

Authors:  Y Yoshiyama; L Grenier; P Gourde; M Simard; L Lin; N J Morin; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 8.  Cefetamet pivoxil clinical pharmacokinetics.

Authors:  R A Blouin; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

9.  Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.

Authors:  J D Knudsen; N Frimodt-Møller; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

10.  Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.

Authors:  G Potel; J Caillon; F Le Gallou; D Bugnon; P Le Conte; J Raza; J Y Lepage; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.